Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Younger AML Patients with Adverse Biology Routinely Receive It?

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jeffrey Lancet
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jeffrey Lancet
0 views
October 18, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

01:29
Incyte

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Acute Myeloid Leukemia
15:38
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

2019 AML State of the Art Update: How to Treat Newly Diagnosed and S…

Feat. S. Luger
16:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

CAR T-Cells in AML: An Effective Therapy Requires Optimization of th…

Feat. E. Budde
13:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Novel Strategies in High Risk AML: Clinical and Molecular Features

Feat. J. Welch
16:06
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Chemotherapy-Free Approach in Relapsed/Refractory AML: Antibody-Drug…

Feat. J. DiPersio
15:39
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

All Older AML Patients and Younger Patients with Adverse Biology Sho…

Feat. D. Pollyea
17:20
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Youn…

Feat. J. Lancet
15:19
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Use of MRD in AML: Determining Method, Acceptable Endpoint and Progn…

Feat. P. Montesinos
14:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

How to Choose a FLT3 inhibitor in AML in 2019: Discussion on Midosta…

Feat. C. Smith
15:52
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Use of Gemtuzumab in CD33 + AML: Benefit May Be Greatest in Favorabl…

Feat. R. Walter
08:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin …

Feat. A. Skwarska
09:44
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (…

Feat. C. DiNardo
08:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeuti…

Feat. Y. Semba